RISPERDAL 1 MGML Izrael - angleščina - Ministry of Health

risperdal 1 mgml

j-c health care ltd - risperidone - solution - risperidone 1 mg / 1 ml - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

RISPERDAL 1 MG Izrael - angleščina - Ministry of Health

risperdal 1 mg

j-c health care ltd - risperidone - film coated tablets - risperidone 1 mg - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

RISPERDAL 2 MG Izrael - angleščina - Ministry of Health

risperdal 2 mg

j-c health care ltd - risperidone - film coated tablets - risperidone 2 mg - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

RISPERDAL 3 MG Izrael - angleščina - Ministry of Health

risperdal 3 mg

j-c health care ltd - risperidone - film coated tablets - risperidone 3 mg - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

RISPERDAL risperidone 0.5 mg tablet blister pack Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

risperdal risperidone 0.5 mg tablet blister pack

janssen-cilag pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; propylene glycol; maize starch; sodium lauryl sulfate; magnesium stearate; purified talc; iron oxide red; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

RISPERDAL risperidone 1mg/mL oral liquid bottle Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

risperdal risperidone 1mg/ml oral liquid bottle

janssen-cilag pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: purified water; benzoic acid; tartaric acid; sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

RISPERDAL risperidone 2mg tablet Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

risperdal risperidone 2mg tablet

janssen-cilag pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sunset yellow fcf; hypromellose; microcrystalline cellulose; propylene glycol; titanium dioxide; sodium lauryl sulfate; colloidal anhydrous silica; purified talc; magnesium stearate - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

RISPERDAL risperidone 4mg tablet Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

risperdal risperidone 4mg tablet

janssen-cilag pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: indigo carmine; colloidal anhydrous silica; sodium lauryl sulfate; purified talc; quinoline yellow; microcrystalline cellulose; hypromellose; magnesium stearate; propylene glycol; maize starch; lactose monohydrate; titanium dioxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

RISPERDAL risperidone 3mg tablet Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

risperdal risperidone 3mg tablet

janssen-cilag pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: hypromellose; purified talc; lactose monohydrate; maize starch; sodium lauryl sulfate; microcrystalline cellulose; titanium dioxide; quinoline yellow; colloidal anhydrous silica; magnesium stearate; propylene glycol - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

RISPERDAL risperidone 1mg tablet Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

risperdal risperidone 1mg tablet

janssen-cilag pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; sodium lauryl sulfate; propylene glycol; magnesium stearate; colloidal anhydrous silica; maize starch - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).